Last --
Change Today 0.00 / 0.00%
Volume 0.0
GAP On Other Exchanges
All times are local (Market data is delayed by at least 15 minutes).

pharmagap inc (GAP) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMAGAP INC (GAP)

Related News

No related news articles were found.

pharmagap inc (GAP) Related Businessweek News

View More BusinessWeek News

pharmagap inc (GAP) Details

PharmaGap Inc., a biotechnology company, engages in drug development and out-licensing of drug compounds in Canada. The company focuses on the development of peptide therapeutics for the treatment of cancer and other human disease conditions. Its lead drug compound, GAP-107B8, is in the pre-clinical testing stage for the treatment of cancer targeting Protein Kinase C (PKC). The company was founded in 1999 and is based in Ottawa, Canada.

Founded in 1999

pharmagap inc (GAP) Top Compensated Officers

Chief Executive Officer, President and Corpor...
Total Annual Compensation: --
Co-Founder, Director and Member of Independen...
Total Annual Compensation: --
Co-founder, Chief Scientific Officer, Managin...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Chief Operating Officer and Vice President of...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

pharmagap inc (GAP) Key Developments

Pharmagap Inc. To Be Moved To NEX From TSX Venture Exchange

Further to Pharmagap Inc.’s press releases of February 4, 2013 and February 6, 2013 and in accordance with TSX Venture Policy 2.5, the company has not maintained the requirements for a TSX Venture Tier 2 company. Therefore, effective at the opening on May 9, 2013, the company's listing will transfer to NEX, the company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Toronto to NEX. As of May 9, 2013, the company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. Further to the TSX Venture bulletin dated May 6, 2013, trading in the shares of the company will remain suspended.

Pharmagap Inc. Announces Corporate Secretary Changes

Pharmagap Inc. announced that Robert C. McInnis, President and Chief Executive Officer has assumed the role of Corporate Secretary on the resignation of Ms. Sue Kavanagh from that position effective immediately.

PharmaGap Receives Notice Of Pending Transfer To NEX Exchange

PharmaGap Inc. received notice from the TSX Venture Exchange (the Exchange) advising the Company of deficiencies in the exchange's Tier 2 listing requirements related to a Working Capital and Assets and Operations. The Exchange has placed the Company on notice, with a deadline of May 7, 2013 by which time the Company is required to provide a submission to the Exchange evidencing that it meets the Tier 2 continued listing requirements. If the Company is not able to satisfy the Exchange that it meets all Tier 2 continued listing requirements by May 7, 2013, the Exchange will proceed to transfer the Company's listing to NEX, without further notice. At this time the company does not expect to make a submission to Exchange to seek delay of transfer to NEX.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GAP:CN C$0.00 CAD 0.00

GAP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GAP.
View Industry Companies

Industry Analysis


Industry Average

Valuation GAP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMAGAP INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at